血清miR-29a、COX-2水平与老年晚期乳腺癌病人化疗预后的相关性

doi:10.3969/j.issn.1003-9198.2022.05.007

摘要/Abstract

摘要： 目的观察血清微小RNA-29a(miR-29a)、环氧化酶-2(COX-2)水平与老年晚期乳腺癌病人化疗预后的关系。方法回顾性分析本院2018年1月至2020年1月接受TAC(紫杉醇+吡柔比星+环磷酰胺)方案化疗后并接受至少1个月随访的114例老年晚期乳腺癌病人临床资料,收集病人基线资料及化疗前血清miR-29a、COX-2水平,随访1个月时评估病人化疗预后,分析化疗前血清糖类抗原125(CA125)、CA153、基质金属蛋白酶2(MMP-2)、miR-29a、COX-2水平与老年晚期乳腺癌病人化疗预后的关系及对预后的预测价值。结果 114例老年晚期乳腺癌病人中,有44例预后不良,有70例预后良好;回归分析结果显示,CA125、CA153、MMP-2、miR-29a相对表达量、COX-2表达上调与老年晚期乳腺癌病人化疗预后不良发生有关;ROC结果显示,CA125、CA153、MMP-2、miR-29a相对表达量、COX-2预测预后不良发生风险的AUC均＞0.80,均有一定预测价值。结论 miR-29a相对表达量、CA125、CA153、MMP-2及COX-2与老年晚期乳腺癌病人化疗预后不良密切相关。

关键词: 晚期乳腺癌, 化疗, 微小RNA-29a, 环氧化酶-2, 肿瘤标志物, 基质金属蛋白酶2, 预后

Abstract: Objective To observe the relationship of serum levels of microRNA-29a (miR-29a) and cyclooxygenase-2 (COX-2) with prognosis of chemotherapy in the elderly patients with advanced breast cancer. Methods The clinical data of 114 elderly patients with advanced breast cancer who were followed up for at least one month after receiving TAC (paclitaxel + pirarubicin + cyclophosphamide) regimen for chemotherapy from January 2018 to January 2020 in our hospital were retrospectively analyzed. The baseline data of the patients were collected, and the serum levels of crbohydrate antigen 125(CA125),CA153,matrix metalloproteinase-2 (MMP-2), miR-29a, COX-2 of patients were detected before chemotherapy. The prognosis of chemotherapy was evaluated. Regression analysis was used to examine the influencing factors of the prognosis of the elderly patients with advanced breast cancer. Results Among 114 elderly patients with advanced breast cancer, 44 cases had poor prognosis, and 70 cases had good prognosis. Regression analysis showed that the up-regulated expression of CA125, CA153, MMP-2, COX-2, and relative expression of miR-29a were associated with poor prognosis of chemotherapy in the elderly patients with advanced breast cancer. ROC curve was drawn and showed that the AUC of CA125, CA153, MMP-2, relative expression of miR-29a and COX-2 in predicting the risk of poor prognosis were all >0.80, which had certain predictive value. Conclusions The relative expression of miR-29a, CA125, CA153, MMP-2 and COX-2 are closely related to poor prognosis of the elderly patients with breast cancer.

Key words: advanced breast cancer, chemotherapy, microRNA-29a, cyclooxygenase-2, tumor markers, matrix metalloproteinase-2, prognosis

中图分类号:

R 737.9

王绪娟, 罗永鑫, 李成强, 王汝晋, 向敏. 血清miR-29a、COX-2水平与老年晚期乳腺癌病人化疗预后的相关性[J]. 实用老年医学, 2022, 36(5): 459-462.

WANG Xu-juan, LUO Yong-xin, LI Cheng-qiang, WANG Ru-jin, XIANG Min. Correlation between serum levels of miR-29a, COX-2 and prognosis of chemotherapy in elderly patients with advanced breast cancer[J]. Practical Geriatrics, 2022, 36(5): 459-462.

参考文献

[1] TESHOME M.Role of operative management in stage iv breast Cancer[J]. Surg Clin North Am,2018,98(4):859-868.
[2] CARSON E,DEAR R.Advanced breast cancer: an update to systemic therapy[J]. Aust J Gen Pract,2019,48(5):278-283.
[3] YOSHIMURA T,ADACHI M,KOSHIISHI H,et al.Assessment for local treatment for elderly breast cancer cases[J]. Gan To Kagaku Ryoho,2020,47(13):2098-2100.
[4] PETRI B J,KLINGE C M.Regulation of breast cancer metastasis signaling by miRNAs[J]. Cancer Metastasis Rev,2020,39(3):837-886.
[5] 黄智述,任黔川.miR-29a在宫颈癌组织中的表达及其上调后对宫颈癌细胞恶性生物学行为的影响[J]. 中国现代医学杂志,2017,27(18):22-27.
[6] 王慧玲,林兴滔,区应亮,等.miR-29a调控HDAC4促肝癌细胞增殖和转移的机制研究[J]. 胃肠病学和肝病学杂志,2017,26(4):381-385.
[7] 蔡海瑜,刘爱珍,宋芷霜,等.雌激素通过上调COX-2的表达影响宫颈癌Hela细胞的增殖及化疗敏感性[J]. 实用医学杂志,2020,36(11):1442-1446.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013版)[J]. 中国癌症杂志,2013,23(8):637-684.
[9] PATRIARC S,FERRETTI S,ZANETTI R.TNM Classifiction of malignant tumours -Eighth edition: which news[J]. Epidemiol Prev,2017,41(2):140-143.
[10] WATANABE H,OADA M,KAJI Y,et al.New response evaluation criteria in solid Tumours-Revised RECIST Guideline (Version 1.1)[J]. Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[11] 管秀雯,马飞,徐兵河.我国老年晚期乳腺癌患者生存情况及治疗特点分析[J]. 国际肿瘤学杂志,2019,46(11):657-661.
[12] LI J X,LIU L Y,FENG Z W,et al.Tumor markers CA153,CA125,CEA and breast cancer survival by molecular subtype: a cohort study[J]. Breast Cancer,2020,27(4):621-630.
[13] FAN Y,CHEN X J,LI H J.Clinical value of serum biomarkers CA153,CEA,and white blood cells in predicting sentinel lymph node metastasis of breast cancer[J]. Int J Clin Exp Pathol,2020,13(11):2889-2894.
[14] 罗俊波,郑瑞锋,王彦威,等.血清MMP-2、MMP-9和CA15-3水平在乳腺癌中的临床病理学意义及预后价值[J]. 实用癌症杂志,2019,34(2):195-199.
[15] 罗和生,万一圆,黄晓东.微小RNA在恶性肿瘤诊断与治疗中的研究进展[J]. 新乡医学院学报,2018,35(12):1134-1138.
[16] 王旭,刘勇,吴冶.与肿瘤恶性增殖及侵袭的相关性分析[J]. 临床和实验医学杂志,2020,19(5):490-493.
[17] 张涛,梅亚男.Ki67,p53和PTEN在乳腺癌中的表达及临床意义[J]. 中国妇幼保健,2017,32(13):2862-2865.
[18] WYATT G L,CRUMP L S,YOUNG C M,et al.Cross-talk between SIM2s and NFκB regulates cyclooxygenase 2 expression in breast cancer[J]. Breast Cancer Res,2019,21(1):131.
[19] ASGHAR K,LOYA A,RANA I A,et al.Association between cyclooxygenase-2 and indoleamine 2,3-dioxygenase expression in breast cancer patients from pakistan[J]. Asian Pac J Cancer Prev,2019,20(11):3521-3525.